Characteristics | Post treatment | 3-month follow-up | 12-month follow-up | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
at baseline | PF | RP | BP | GH | VT | SF | RE | MH | PF | RP | BP | GH | VT | SF | RE | MH | PF | RP | BP | GH | VT | SF | RE | MH |
Adjusted R-square | 0.62 | 0.12 | 0.17 | 0.39 | 0.50 | 0.27 | 0.15 | 0.41 | 0.45 | 0.25 | 0.23 | 0.47 | 0.59 | 0.36 | 0.19 | 0.32 | 0.64 | 0.21 | 0.33 | 0.29 | 0.46 | 0.55 | 0.35 | 0.37 |
Age: 35 yrs or older | a | a | a | a | a | a | 0.41* | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a |
Living situation | a | a | a | a | -0.32** | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a |
Employment | a | a | a | a | a | a | a | a | a | a | a | a | -0.30* | a | a | a | a | a | a | a | a | a | a | a |
Generalized SAD | -0.22* | a | a | a | a | a | a | -0.28* | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a |
Benzodiazepine use | 0.23* | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a |
SPS (total) | a | a | a | a | a | a | a | a | a | 0.39* | a | 0.29* | a | a | a | a | a | a | a | a | a | 0.49** | a | a |
SIAS (total) | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | a | -0.32* | a | a |
SCL-90-R depression | a | a | -0.44** | a | a | a | a | a | a | -0.64** | a | a | a | a | -0.46** | a | a | a | a | a | a | -0.41* | -0.61** | a |